Real-time financial, economic, and global news with market-focused context and analysis.
Coverage spans equities, macroeconomic data, commodities, currencies, technology, politics, and global events—paired with analysis that highlights why each development matters for traders and investors. From breaking headlines to hourly market snapshots and in-depth articles, the News Hub is designed to help you stay informed, oriented, and ahead of market-moving events.
Neumora Therapeutics announced their Q4 and full-year 2025 financial results alongside key clinical progress updates. Highlights include positive Phase 1b data reinforcing NMRA-511's potential in Alzheimer's disease agitation, full enrollment of KOASTAL-2 and -3 studies with expected data readout in Q2 2026, advancement of NMRA-898 for schizophreni…
Royalty Pharma announced a $500 million co-funding collaboration with Johnson & Johnson over 2026-2027 to develop JNJ-4804, a novel co-antibody therapy targeting chronic immune-mediated diseases by blocking IL-23 and TNF pathways. This partnership builds on Royalty Pharma's strong immunology investment track record and leverages J&J's leadership in…
Sight Sciences announced that the U.S. District Court for the District of Delaware upheld a jury verdict finding Alcon willfully infringed three of Sight Sciences' patents related to glaucoma treatment devices. The Court awarded Sight Sciences $34 million in past damages plus supplemental damages and interest, and granted an ongoing 10% royalty on …
PMGC Holdings Inc. (NASDAQ: ELAB) filed its 2025 Annual Report highlighting a 43% growth in total assets to $12.87 million, driven by three strategic acquisitions in precision manufacturing and specialty IT hardware packaging serving aerospace, defense, and semiconductor sectors. The company also advanced its biopharmaceutical subsidiary, Northstri…
Connect Biopharma announced a $20.2 million private placement financing led by existing investor Panacea Venture, extending its cash runway through the second half of 2027. The funds will support the development of its clinical-stage drug candidates targeting inflammatory diseases such as asthma and COPD, particularly the next-generation antibody r…
Connect Biopharma announced promising Phase 3 clinical trial results of its drug rademikibart for moderate-to-severe atopic dermatitis. The 52-week study demonstrated rapid, durable efficacy with a high percentage of patients achieving significant skin clearance and an excellent safety profile comparable to placebo. The data were presented at the 2…
Aquestive Therapeutics announced successful completion of a Type A meeting with the FDA regarding the resubmission of the New Drug Application (NDA) for Anaphylm (dibutepinephrine) sublingual film, reaffirming plans to resubmit in Q3 2026. The FDA provided clarifying feedback on pharmacokinetic and human factor study designs, and the company is pre…
Smart Share Global Limited, a Nasdaq-listed consumer tech company providing mobile device charging services in China, has been granted an exception by Nasdaq staff regarding the late filing of its interim financial report for the half-year ended June 30, 2025. The company must file the report by June 29, 2026 to maintain compliance with Nasdaq list…
Terrestrial Energy announced its Q4 and full year 2025 results highlighting selection by Texas A&M for commercial IMSR plant deployment, NRC acceptance of principal design criteria, DOE awards for reactor and fuel pilot projects, and a successful business combination raising $292 million. The company strengthened its position in the US energy marke…
Digital Realty announced the final close of its first U.S. hyperscale data center fund, securing $3.25 billion from institutional investors to own and develop major hyperscale data centers across key U.S. metro areas. The company will manage the fund with a 20% stake and has added two senior executives to strengthen its private capital platform, ai…
PDS Biotechnology Corporation reported financial results for 2025 and updated on clinical progress, including a Phase 3 trial amendment for PDS0101 that incorporates progression-free survival as an interim primary endpoint, potentially shortening trial duration and costs while preserving overall survival as the full approval endpoint. Early promisi…
Connect Biopharma announced positive topline results from its Phase 1 clinical study of intravenous rademikibart, a next-generation anti-IL-4Rα antibody, demonstrating rapid and sustained lung function improvements in asthma and COPD patients. The drug produced clinically meaningful FEV1 increases as early as 15 minutes after dosing and was well to…
Seer, Inc. announced that the U.S. Patent and Trademark Office's Patent Trial and Appeal Board upheld 23 claims of its crucial patent for nano- and microparticle protein enrichment technology used in its Proteograph platform. The decision affirms the intellectual property strength of Seer's proprietary proteomic analysis methods, securing its compe…
Aura Biosciences reported strong financial results for Q4 and full year 2025, highlighted by accelerated enrollment in its global Phase 3 CoMpass trial for early choroidal melanoma with enrollment completion expected mid-2026 and topline data anticipated in the second half of 2027. The company is also progressing clinical trials in bladder cancer (…
Bitfarms Ltd., a North American digital infrastructure and energy company specializing in data centers and energy infrastructure for high-performance computing including AI workloads, will participate in a Jefferies Virtual Power x Data Center Conference fireside chat featuring CEO Ben Gagnon and CFO Jonathan Mir.
BridgeBio Pharma has submitted a New Drug Application (NDA) to the FDA for BBP-418, a potential first and only treatment for limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). The submission includes positive interim Phase 3 FORTIFY trial data demonstrating significant improvements in ambulation and pulmonary function, and a favorable safety pr…
BeyondSpring Inc., a clinical-stage biopharmaceutical company, announced a poster presentation at the 2026 AACR Annual Meeting showcasing data on the combination of Plinabulin with antibody-drug conjugates and immune checkpoint inhibitors, highlighting enhanced antitumor efficacy. This presentation underscores Plinabulin's potential in cancer immun…
Medicus Pharma announced key opinion leader validation of its Phase 2 SkinJect clinical data demonstrating an approximately 80% overall response rate in treating nodular basal cell carcinoma. The data supports continued clinical development with a focus on a 200µg dose regimen and highlights SkinJect's potential as a non-surgical treatment alternat…
BullFrog AI Holdings has entered a commercial agreement with a top 5 global pharmaceutical company to apply its AI-driven bfLEAP® platform to identify and prioritize novel drug targets for major depressive disorder (MDD). This collaboration aims to accelerate the customer's drug discovery and clinical development programs for MDD, a market valued a…
Palvella Therapeutics announced a scientific publication in the Journal of Vascular Anomalies outlining the unique challenges of treating microcystic lymphatic malformations (LMs) and emphasizing the unmet medical need. The review underscores clinical distinctions between microcystic and macrocystic LMs and supports Palvella's QTORIN™ 3.9% rapamyci…
Red Cat Holdings, Inc., a U.S.-based provider of advanced multi-domain drone and robotic solutions for defense and national security, has acquired Apium Swarm Robotics. This acquisition enhances Red Cat's ability to deliver intelligent, coordinated swarming autonomy for drones and uncrewed surface vessels, supporting operations in contested and com…
Bicara Therapeutics reported strong fourth quarter and full year 2025 financial results alongside significant clinical progress including the initiation of Phase 3 for their lead drug candidate ficerafusp alfa in HPV-negative head and neck cancer. The company confirmed 1500mg as the optimal weekly dose, is advancing less frequent dosing schedules, …
Biogen announced FDA approval of a high dose regimen of SPINRAZA (nusinersen) for treating spinal muscular atrophy (SMA). The approval is based on the pivotal DEVOTE study that demonstrated significant motor function improvements in infants with SMA and a safety profile consistent with the established low dose regimen. The new regimen offers higher…
Asure Software appointed Tiffany Mortimer as Chief Transformation & People Officer to lead its operational and organizational transformation initiatives, aligning with the company's focus on advancing AsureCentral and AI-enhanced human capital management solutions. Mortimer's extensive experience in SaaS operational leadership and transformation is…
Anavex Life Sciences Corp. provides a regulatory update on its lead drug candidate blarcamesine, highlighting ongoing discussions with the European Medicines Agency (EMA) for early Alzheimer’s disease following the withdrawal of EU marketing authorization application. Additional data has been submitted to the U.S. FDA to explore pathways toward a N…
